Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (2024)
32 slides from Astrazeneca's investor day presentation, 2024
Slide 1: Investor Day 2024: Speaker biographies
Investor Day 2024 Unlocking growth to 2030 and beyond Speaker biographies Ambition 2030 Investor Day • 2024
Slide 2: Pascal Soriot
Pascal Soriot Chief Executive Officer Pascal is Executive Director and Chief Executive Officer at AstraZeneca. He has been a member of the Board and CEO since October 2012. Pascal has a passion for science and medicine as well as a successful track record of managing change, executing strategy and l
Slide 3: Aradhana Sarin
Aradhana Sarin Executive Director and Chief Financial Officer Aradhana is Executive Director and Chief Financial Officer at AstraZeneca. She has been a member of the Board and CFO since August 2021. Prior to her current role, Aradhana was CFO for Alexion. Aradhana joined Alexion in 2017 and was resp
Slide 4: Sharon Barr
Sharon Barr Executive Vice President, BioPharmaceuticals R&D Sharon was appointed as Executive Vice-President, BioPharmaceuticals Research & Development in August 2023. She is responsible for discovery through to late- stage development across CVRM and Respiratory & Immunology. Prior to this role, S
Slide 5: Ruud Dobber
Ruud Dobber Executive Vice President and President, BioPharmaceuticals Ruud was appointed Executive Vice-President, BioPharmaceuticals Business Unit in January 2019 and is responsible for product strategy and commercial delivery for Cardiovascular, Renal and Metabolism, Respiratory and Immunology, a
Slide 6: Marc Dunoyer
Marc Dunoyer Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca Marc became Chief Executive Officer of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July 2021. He had previously served as an Executive Director and AstraZeneca’s Chief Fin
Slide 7: Dave Fredrickson
Dave Fredrickson Executive Vice President, Oncology Business Dave was appointed Executive Vice-President, Oncology Business Unit in October 2017 and is responsible for driving growth and maximising the global commercial performance of the AstraZeneca global Oncology portfolio. Previously, Dave serve
Slide 8: Susan Galbraith
Susan Galbraith Executive Vice President, Oncology R&D Susan was appointed as Executive Vice-President, Oncology Research & Development in July 2021, with responsibility for transforming the productivity and scientific output from Oncology R&D. Over her career, Susan has helped develop 12 approved m
Slide 9: Iskra Reic
Iskra Reic Executive Vice President, V&I Iskra is an EVP for V&I, with responsibility across the pipeline and portfolio, including R&D, medical affairs, marketing, and commercial operations. In 2021, Iskra was appointed Head of the Vaccines & Immune Therapies division, and supported the delivery of
Slide 10: Andrew Barnett
Andrew Barnett Vice President, Investor Relations Andy is Head of Investor Relations at AstraZeneca. Andy joined AstraZeneca in 2019, initially as Global Head of Commercial for Immuno-Oncology, followed by Global Franchise Head for Lynparza, DDR and Established Oncology within the Oncology Business
Slide 11: Maria Belvisi
Maria Belvisi Senior Vice President and Head of R&D Early Respiratory and Immunology Maria joined AstraZeneca in 2017 from Imperial College London, where she was Professor of Respiratory Medicine. Maria is responsible for bringing early science ideas and assets from pre-clinical through to late-stag
Slide 12: Elisabeth Björk
Elisabeth Björk Senior Vice President, Late CVRM Elisabeth is a scientific leader with more than 30 years’ experience in treating patients with chronic conditions. After training as an endocrinologist, Elisabeth worked for 15 years in clinical practice and diabetes research at Uppsala University Hos
Slide 13: Caterina Brindicci
Caterina Brindicci Senior Vice President, Late R&I As Senior Vice President & Global Head for Late Respiratory & Immunology, Caterina leads a team of more than 500 across seven countries globally with accountability for the exciting late clinical development portfolio, advancing potential medicines
Slide 14: Robert Chen
Robert Chen Global Head of Lymphoma and Head of Clinical Development, Oncology R&D Based in Cambridge, Robert is the Global Head of Lymphoma and Head of Clinical Development in AstraZeneca Haematology R&D. Dr Chen previously held the position of Executive Medical Director at Autolous Therapeutics, l
Slide 15: Seng Cheng
Seng Cheng Senior Vice President, Head of Research and Product Development, Alexion Seng is responsible for drug discovery, process development and clinical supply as well as clinical biomarkers and bioanalytical discovery, rare disease diagnostics and bioinformatics, supporting Alexion’s pipeline f
Slide 16: Mark Cobbold
Mark Cobbold Senior Vice President, IO Discovery and Cell Therapy Mark Cobbold is Senior Vice President of IO Discovery and Cell Therapy at AstraZeneca and is responsible for the basic science and early drug development in cell therapy, immuno-oncology and immune engagers. Mark is an immunologist an
Slide 17: Martin Cowie
Martin Cowie Interim Senior Vice President, Late-Stage Development, CVRM Professor Martin Cowie, Therapy Area Head for Late Stage CVRM, joined AstraZeneca full-time two years ago after a 25-year career as a clinical academic cardiologist at Imperial College London where he led the advanced heart fai
Slide 18: Regina Fritsche Danielson
Regina Fritsche Danielson Senior Vice President and Head of R&D Early CVRM Associate Professor, Dr Regina Fritsche-Danielson is accountable for the small and large molecule as well as new modalities research and development from early target discovery to Phase III investment decision, with a researc
Slide 19: Mark Esser
Mark Esser Vice President, Early V&I R&D Mark joined AstraZeneca in 2010 and is currently Vice President of Vaccines and Immune Therapies early R&D. He is responsible for all antibody and vaccine discovery, research and translational medicine for AstraZeneca’s infectious disease programs bringing ea
Slide 20: Nicola Heffron
Nicola Heffron Senior Vice President, Head of Global Marketing and Market Access, Alexion Nicola leads Alexion’s Global Marketing and Market Access team focused on global marketing, global commercial strategy, pricing and market access. Prior to joining Alexion, Nicola served as the Chief Operating
Slide 21: Matt Hellmann
Matt Hellmann Vice President, Early Oncology Development Matthew Hellmann, MD, is Vice President, Early Oncology Development, at AstraZeneca. In this role, he is responsible for the strategic planning and execution of the early oncology portfolio, as well as translational medicine and cancer biomark
Slide 22: Leora Horn
Leora Horn Global Clinical Head for Lung Cancer and Lung Cancer Strategy, Oncology R&D At AstraZeneca, Leora is responsible for leading global research and development efforts in lung cancer, partnering with lung cancer teams across AstraZeneca to rapidly progress research and deliver on a broader c
Slide 23: Mina Makar
Mina Makar Senior Vice President, Global CVRM Mina leads the US marketing, sales and access strategy for AstraZeneca’s Respiratory & Immunology therapeutic area and is a member of the US Leadership Team. Since joining AstraZeneca in 1999, Mina has held roles in the US and globally. Most recently, he
Slide 24: Cristian Massacesi
Cristian Massacesi Chief Medical Officer and Oncology Chief Development Officer Appointed in 2021, Cristian leads AstraZeneca’s late-stage Oncology portfolio through global clinical development and regulatory submissions. Cristian also leads patient safety and quality assurance activities for the en
Slide 25: Ingrid Mayer
Ingrid Mayer Vice President, Global Clinical Strategy Head, Breast and Gynecologic Cancers, Oncology R&D Appointed in 2021, Ingrid, a breast medical oncologist, is responsible for organising and leading strategic planning efforts, decision-making and initiatives aimed at defining and developing the
Slide 26: Pablo Panella
Pablo Panella Senior Vice President, Global R&I As Senior Vice-President, Global Respiratory & Immunology, Pablo is responsible for AstraZeneca’s global R&I business and strategy for the Company’s current and future R&I portfolio of medicines. Prior to his current role, Pablo was Senior Vice-Preside
Slide 27: Gianluca Pirozzi
Gianluca Pirozzi Senior Vice President, Head of Development and Safety, Alexion Gianluca joined Alexion in October 2019 and currently leads the company’s integrated Development, Regulatory and Safety organisation. Previously, he served in various roles at Sanofi Genzyme, including Head of Developmen
Slide 28: Osama Rahma
Osama Rahma Vice President, Global Clinical Strategy Head, GI Oncology, Oncology R&D Osama is a Gastrointestinal Oncologist, appointed in 2021 to lead AstraZeneca Strategy in GI Oncology. He is responsible for the late clinical development across all GI Cancers. Prior to joining AstraZeneca, Osama s
Slide 29: Puja Sapra
Puja Sapra Senior Vice President, Biologics Engineering and Oncology Targeted Discovery Puja is the Senior Vice President of the Biologics Engineering & Oncology Targeted Discovery. In this role, she leads the discovery groups responsible for development of tumor-targeting modalities including Antib
Slide 30: Nina Shah
Nina Shah Global Clinical Head, Multiple Myeloma Nina joined AstraZeneca in July 2022 as the Global Clinical Head of Multiple Myeloma Clinical Development and Strategy. Dr Shah’s career has focused on early and late phase trials on immunotherapy and patient experience in multiple myeloma. Prior to j
Slide 31: Sunil Verma
Sunil Verma Senior Vice President, Global Medical Affairs Sunil Verma is Global Head of Oncology, Medical in AstraZeneca. His leadership is focused on advancing the practice of cancer care through robust evidence generation to address unmet needs, scientific partnerships and redefining the future ca
Slide 32: Anas Younes
Anas Younes Senior Vice President, Global Head of Haematology, Oncology R&D Anas joined AstraZeneca in 2020 as the Senior Vice President, Global Head of Haematology (Early and Late Stage). As a trained clinician-scientist, Dr Younes has spent more than 25 years caring for patients with lymphoma. Pri